What We Do:
- Plans and directs studies necessary to identify, evaluate, develop, and obtain FDA approval for new medications and devices to treat Substance Use Disorders (SUD) and related medical and psychiatric conditions;
- Develops and administers a program on basic and clinical research to (a) develop innovative pharmacological and non-pharmacological approaches for SUDs and related medical and psychiatric conditions and (b) investigate the medical consequences of drug abuse, including HIV/AIDS;
- Supports research to identify valid and reliable outcome measures for clinical trials of therapeutics for SUDs;
- Supports training in the pre-clinical and clinical research of therapeutics for SUDs;
- Collaborates with: (a) the pharmaceutical sector in both the United States and abroad, and (b) other federal therapeutic development programs;
- Works closely with FDA in assuring that research designed to demonstrate the clinical efficacy of new compounds is evaluated and approved in an expeditious manner; and
- Disseminates the knowledge acquired by the DTMC funded research.
Research Programs:
- Pharmacotherapies Development Program
- The Addiction Treatment Discovery Program (ATDP)
- Regulatory Affairs Program
- Behavioral Therapy Development Program
- Device Development for Substance Use Disorders
- Digital Therapeutics Development Program
- Clinical Trial Outcomes Development Program
- NIDA Drug Supply Program
Division Listings:
- Office of the DTMC Director (OD)
- Chemistry and Pharmaceutics Branch (CPB)
- Clinical/Medical Branch (CMB)
- Clinical Research Grants Branch (CRGB)
- Medications Discovery and Toxicology Branch (MDTB)
- Regulatory Affairs Branch (RAB)
Staff Listings:
Mailing Address:
Division of Therapeutics & Medical Consequences
National Institute on Drug Abuse
C/O NIH Mail Center
3WFN MSC 6016
16071 Industrial Drive – Dock 11
Gaithersburg, MD 20892*
*(Use 20892 for U.S. Postal Service, 20877 for UPS and FedEx)
(301) 443-6173 (phone)
(301) 443-2599 (fax)